Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.
Anton PozniakJason FlammAndrea AntinoriMark BlochDouglas WardJuan BerenguerPierre CôtéKristen AndreattaWilliam GarnerJavier SzwarcbergThai Nguyen-ClearyDamian J McCollDavid PiontkowskyPublished in: HIV clinical trials (2017)
E/C/F/TDF is safe and effective and reduces NNRTI-associated neuropsychiatric symptoms for virologically suppressed HIV-positive adults switching from an NNRTI plus FTC/TDF-based regimen.